Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TRASTUZUMAB-DTTB Cause Product use in unapproved indication? 89 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 89 reports of Product use in unapproved indication have been filed in association with TRASTUZUMAB-DTTB. This represents 17.9% of all adverse event reports for TRASTUZUMAB-DTTB.

89
Reports of Product use in unapproved indication with TRASTUZUMAB-DTTB
17.9%
of all TRASTUZUMAB-DTTB reports
4
Deaths
83
Hospitalizations

How Dangerous Is Product use in unapproved indication From TRASTUZUMAB-DTTB?

Of the 89 reports, 4 (4.5%) resulted in death, 83 (93.3%) required hospitalization, and 11 (12.4%) were considered life-threatening.

Is Product use in unapproved indication Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TRASTUZUMAB-DTTB. However, 89 reports have been filed with the FAERS database.

What Other Side Effects Does TRASTUZUMAB-DTTB Cause?

Diarrhoea (150) Nausea (66) Pyrexia (65) Off label use (63) Anaemia (61) Vomiting (46) Hypokalaemia (43) Chills (40) Dyspnoea (37) Acute kidney injury (31)

What Other Drugs Cause Product use in unapproved indication?

DUPILUMAB (33,452) DICLOFENAC (12,197) METHOTREXATE (8,930) PREDNISONE (7,625) RITUXIMAB (7,519) MYCOPHENOLATE MOFETIL (5,910) ACETAMINOPHEN (5,819) CYCLOPHOSPHAMIDE (5,750) RISPERIDONE (5,551) TACROLIMUS (5,057)

Which TRASTUZUMAB-DTTB Alternatives Have Lower Product use in unapproved indication Risk?

TRASTUZUMAB-DTTB vs TRASTUZUMAB EMTANSINE TRASTUZUMAB-DTTB vs TRASTUZUMAB-PKRB TRASTUZUMAB-DTTB vs TRASTUZUMAB-QYYP TRASTUZUMAB-DTTB vs TRAVOPROST TRASTUZUMAB-DTTB vs TRAZODONE

Related Pages

TRASTUZUMAB-DTTB Full Profile All Product use in unapproved indication Reports All Drugs Causing Product use in unapproved indication TRASTUZUMAB-DTTB Demographics